Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03080792
Other study ID # PRESENT-P/ S-030/2016
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date November 2016
Est. completion date June 2019

Study information

Verified date June 2021
Source University Hospital Heidelberg
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The PRESENT-P study is a one-arm exercise intervention study for hematological cancer patients prior allogeneic stem cell transplantation (allo-HCT). This pilot study will investigate in a prehabilitation approach the safety and feasibility of high-intensity exercise program directly prior transplantation.


Description:

The major objective of PRESENT-P is to investigate the feasibility and safety of a high intensity endurance exercise training (HIIT) and progressive resistance exercise prior allo-HCT. This multicenter pilot study will include n=30 patients. Patients perform two supervised exercise sessions per week. Recruitment take place 6-12 weeks prior allogeneic stem cell transplantation. Further aims of this pilot study are: to estimate the number of eligible patients, evaluate the recruitment procedure, and to explore the effect of HIIT prior allo-HCT on maximal oxygen uptake (VO2peak),submaximal endurance capacity, muscle strength, patient-reported-outcomes including QoL and physical functioning.


Recruitment information / eligibility

Status Terminated
Enrollment 14
Est. completion date June 2019
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Hematological cancer, e.g. AML, CLL, MM - Scheduled for allo-HCT at the University Clinic Heidelberg or other cooperation sites within the next 4-12 weeks - Patients = 18 years of age - Sufficient German language skills - Willing/ able to train at the provided exercise facilities twice per week and to take part in the scheduled testing - Signed informed consent Exclusion Criteria: - Heart insufficiency > NYHA III or uncertain arrhythmia - Uncontrolled hypertension - Severe renal dysfunction (GFR < 30%, Creatinine> 3mg/dl) - Reduced standing or walking ability - Insufficient hematological capacity (either hemoglobin value below 8 g/dl or thrombocytes below 30.000/µL) - Any other comorbidities that preclude participation in the exercise programs - Engaging in systematic intense exercise training (at least 1h twice per week)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Experimental: moderate to high-intensity exercise
2x per week endurance exercise (continuous moderate and high intensity intervall training on a cycle ergometer) and progressive resistance training (machine based hypertrophy training)

Locations

Country Name City State
Germany University of Colone Cologne
Germany University Hospital Carl Gustav Carus Dresden Dresden
Germany UCT Frankfurt / Hospital North-West Frankfurt
Germany Medical Center - University Freiburg Freiburg
Germany Heidelberg University Hospital Heidelberg

Sponsors (4)

Lead Sponsor Collaborator
University Hospital Heidelberg University Hospital Dresden, University Hospital Freiburg, University of Cologne

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of supervised high-intensity aerobic exercise training and high-intensity resistance training prior allo-HCT in hematological cancer patients. Measured as adherence to the training protocol Adherence is defined as >50% of prescribed exercise sessions completed. 4-12 weeks
Primary Safety of supervised high-intensity exercise aerobic exercise training and high-intensity resistance training prior allo-HCT in hematological cancer Minor and Major adverse events that are related to the exercise intervention 4-12 weeks
Secondary Change in maximal oxygen uptake (VO2peak), assessed in a maximal incremental exercise test (CPET) on a cycle ergometer 4-12 weeks
Secondary Change in submaximal endurance performance, assessed in a 6-minute walk test (6MWT) 4-12 weeks
Secondary Change in maximal voluntary isometric contraction (MVIC) in a stationary dynamometer test 4-12 weeks
Secondary Change in maximal voluntary isometric hand-grip strength 4-12 weeks
Secondary Change in Quality of Life (QoL) European Research and Treatment in Cancer Quality of Life Questionnaire (EORTC QLQ-C30) 4-12 weeks
Secondary Change in Fatigue Multidimensional Fatigue Inventory, MFI 20 4-12 weeks
Secondary Change in depression Center for Epidemiologic Studies Depression Scale, CES-D 4-12 weeks
Secondary Body Composition Bioelectrical impendance analysis 4-12 weeks
Secondary Estimate the number of eligible patients 12 month
Secondary Evaluation of recruitment procedures Description of possible recruiting procedures in the ambulatory and stationary setting. 12 month